Cargando…
Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises several conditions involving vascular destruction that extends into tissue necrosis. There are several autoimmune and environmental causes implicated in the disease progression; among these is drug-induced vasculitis caused...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667955/ https://www.ncbi.nlm.nih.gov/pubmed/38021694 http://dx.doi.org/10.7759/cureus.47656 |
_version_ | 1785139365248237568 |
---|---|
author | Echevarria, Victoria Pierre, Ednord Quiros, Jorge Eftekhari, Parham |
author_facet | Echevarria, Victoria Pierre, Ednord Quiros, Jorge Eftekhari, Parham |
author_sort | Echevarria, Victoria |
collection | PubMed |
description | Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises several conditions involving vascular destruction that extends into tissue necrosis. There are several autoimmune and environmental causes implicated in the disease progression; among these is drug-induced vasculitis caused by hydralazine use. Hydralazine-induced vasculitis is an uncommon potential complication of the medication and can progress to multisystem involvement and eventually advance to end-organ damage and renal failure. Our patient presented with symptoms of lower extremity edema, dyspnea, and a nonproductive cough eventually resulting in the identification of hydralazine-induced ANCA-associated vasculitis with hypocomplementemia and positive anti-histone antibody. Due to the prevalence of hydralazine as a cardiac drug, physicians managing patients on the medication should have a high index of suspicion of the potential for vasculitis in order to promote prompt diagnosis and treatment of the ANCA-vasculitis. |
format | Online Article Text |
id | pubmed-10667955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-106679552023-10-25 Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Echevarria, Victoria Pierre, Ednord Quiros, Jorge Eftekhari, Parham Cureus Pathology Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises several conditions involving vascular destruction that extends into tissue necrosis. There are several autoimmune and environmental causes implicated in the disease progression; among these is drug-induced vasculitis caused by hydralazine use. Hydralazine-induced vasculitis is an uncommon potential complication of the medication and can progress to multisystem involvement and eventually advance to end-organ damage and renal failure. Our patient presented with symptoms of lower extremity edema, dyspnea, and a nonproductive cough eventually resulting in the identification of hydralazine-induced ANCA-associated vasculitis with hypocomplementemia and positive anti-histone antibody. Due to the prevalence of hydralazine as a cardiac drug, physicians managing patients on the medication should have a high index of suspicion of the potential for vasculitis in order to promote prompt diagnosis and treatment of the ANCA-vasculitis. Cureus 2023-10-25 /pmc/articles/PMC10667955/ /pubmed/38021694 http://dx.doi.org/10.7759/cureus.47656 Text en Copyright © 2023, Echevarria et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pathology Echevarria, Victoria Pierre, Ednord Quiros, Jorge Eftekhari, Parham Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
title | Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
title_full | Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
title_fullStr | Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
title_full_unstemmed | Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
title_short | Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
title_sort | hydralazine-induced anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis |
topic | Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667955/ https://www.ncbi.nlm.nih.gov/pubmed/38021694 http://dx.doi.org/10.7759/cureus.47656 |
work_keys_str_mv | AT echevarriavictoria hydralazineinducedantineutrophilcytoplasmicantibodyancaassociatedvasculitis AT pierreednord hydralazineinducedantineutrophilcytoplasmicantibodyancaassociatedvasculitis AT quirosjorge hydralazineinducedantineutrophilcytoplasmicantibodyancaassociatedvasculitis AT eftekhariparham hydralazineinducedantineutrophilcytoplasmicantibodyancaassociatedvasculitis |